How Are Scientific Advances Transforming Colorectal Cancer Treatment?
Colorectal cancer remains one of the major public health challenges worldwide. Each year, millions of new cases are diagnosed, and this disease causes a high number of deaths. Its development is linked to a combination of genetic and environmental factors, such as diet, alcohol consumption, or imbalances in the gut microbiota. These elements disrupt the natural mechanisms that control cell growth, thereby promoting the appearance and progression of tumors in the colon or rectum.
Research has enabled a better understanding of the molecular mechanisms underlying this cancer. Three main pathways explain its progression: the adenoma-carcinoma sequence, the serrated pathway, and the inflammatory pathway. The first, which is the most common, begins with benign polyps that gradually transform into malignant tumors due to accumulated genetic mutations. The serrated pathway, on the other hand, is often associated with epigenetic changes and specific mutations in the BRAF gene. Finally, the inflammatory pathway is linked to chronic intestinal diseases, such as Crohn’s disease or ulcerative colitis, which create an environment conducive to the formation of cancerous cells.
Tumor cells interact with their environment, known as the tumor microenvironment, which plays a key role in disease progression. This microenvironment includes immune cells, fibers, and molecules that can either promote or inhibit cancer growth. For example, certain intestinal bacteria, such as Fusobacterium nucleatum, can worsen the disease by weakening the immune response or activating cancer signaling pathways.
Recent advances have led to the development of targeted treatments that act directly on the molecular mechanisms of colorectal cancer. Among the most promising advances are immune checkpoint inhibitors, which help the immune system recognize and attack tumor cells. These treatments, combined with a better understanding of the tumor microenvironment, pave the way for more effective and personalized therapeutic strategies.
Current targeted therapies focus on specific signaling pathways, such as those involving the EGFR, VEGF, or BRAF proteins. For example, drugs like cetuximab or bevacizumab block these pathways to slow tumor growth and improve patient survival. However, resistance to treatments remains a major obstacle, often caused by the ability of cancer cells to bypass these blockages.
To overcome these challenges, researchers are exploring combinations of therapies that target multiple mechanisms simultaneously. These approaches aim to prevent tumor cells from developing resistance and to improve the overall effectiveness of treatment. Ongoing clinical trials are also evaluating new therapeutic agents, such as KRAS inhibitors or personalized vaccines, which could revolutionize the management of this disease.
In parallel, the use of biomarkers allows treatments to be tailored based on the genetic characteristics of each tumor. This facilitates more precise medicine, where patients receive therapies adapted to their specific molecular profile.
These advances offer real hope for people with colorectal cancer. Thanks to a better understanding of biological mechanisms and therapeutic innovation, it is now possible to envision more effective, less toxic, and better-adapted treatments for each patient. Research continues to progress, with the goal of transforming this disease into a manageable chronic condition, thereby improving quality of life and survival prospects.
Sources Used
Report Source
DOI: https://doi.org/10.1186/s43556-026-00433-4
Title: Colorectal cancer pathogenesis, oncogenic signaling networks and targeted therapeutic advances
Journal: Molecular Biomedicine
Publisher: Springer Science and Business Media LLC
Authors: Yue Chen; Jiaqi Zhang; Yi Ding; Fang Zhu; Yinnan Chen